Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Otsuka's president characterized the acquisition as strategically significant: Although treatment options for PTSD remain limited, TSND-201 is generating…
Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed…
On April 27, 2026, the FDA awarded Transcend Therapeutics a National Priority Voucher for TSND-201 (methylone) in PTSD, part of the agency's initiative to…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Otsuka agreed to acquire Transcend Therapeutics for $700M upfront plus up to $525M in sales milestones ($1.225B total), gaining TSND-201 (methylone) for PTSD. The asset has FDA Breakthrough Therapy designation (Jul 2025), positive Phase 2 IMPACT-1 data published in JAMA Psychiatry (Feb 2026), and a Phase 3 trial enrolling patients in the U.S. On Apr 27, 2026 the FDA granted TSND-201 a National Priority Voucher in PTSD, further expediting its development. The acquisition was announced Mar 27, 2026 with an expected Q2 2026 close, subject to customary closing conditions; as of early Jun 2026 a deal close had not been publicly confirmed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. / Transcend Therapeutics, Inc. (this deal) | 2026 | $1.2B | — |
| Otsuka Pharmaceutical Co., Ltd. / Avanir Pharmaceuticals, Inc. | 2014 | $3.5B | 41 |
| Otsuka Pharmaceutical Co., Ltd. / 4D Molecular Therapeutics, Inc. | 2025 | $421M | — |
| Otsuka Pharmaceutical Co., Ltd. / Cantargia AB | 2025 | $613M | — |
| Otsuka Pharmaceutical Co., Ltd. / Jnana Therapeutics Inc. | 2024 | $1.1B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Otsuka Pharmaceutical Co., Ltd. deals · Neurology deals